Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | PARP1 | P09874 | 9/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.53 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.53 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660808 | 0.92 | SRC (0.56) | SRCPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL1014333 | 0.91 | SRC (0.55) | SRCPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL1012421 | 0.91 | SRC (0.55) | SRCPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL22631489 | 0.89 | SRC (0.53) | SRCPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL13787116 | 0.89 | SRC (0.53) | SRCPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL4133341 | 0.89 | SRC (0.53) | SRCPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL12779090 | 0.88 | PARP1 (0.53) | SRCPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL12247774 | 0.88 | SRC (0.55) | SRCPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL8960 | 0.88 | SRC (0.52) | SRCPARP1CHEK1PIM1RPS6KA3 | |
| SCHEMBL1012303 | 0.88 | SRC (0.52) | SRCPDPK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260164-B | Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-112239464-B | Quinazoline-4 (3H) -ketone derivative containing 1,3, 4-oxadiazole, preparation method and application | 南京农业大学 | 2022-09-16 | — | — | CN | claimed |
| CN-107245072-A | A kind of preparation method of the triazole compound of Tarceva 1,2,3 | 河南师范大学 | 2017-10-13 | — | — | CN | claimed |
| CN-106946857-A | 3-triazole compounds of Tarceva 1,2,3 with antitumor activity and its preparation method and application | 河南师范大学 | 2017-07-14 | — | — | CN | claimed |
| US-7960545-B2 | Process for the prepartion of erlotinib | NATCO PHARMA LIMITED (IN) | 2011-06-14 | — | — | US | claimed |
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2009-12-10 | — | — | US | claimed |
| WO-2007060691-A2 | A NOVEL PROCESS FOR THE PREPARATION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2007-05-31 | — | — | WO | claimed |
| CN-119504613-B | Coumarin derivative containing quinazoline unit as well as preparation method and application thereof | 江苏海洋大学 | 2026-02-27 | — | — | CN | disclosed |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-119504613-A | Novel coumarin derivative containing quinazoline unit, and preparation method and application thereof | 江苏海洋大学 | 2025-02-25 | — | — | CN | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| WO-1995019169-A2 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR | SUGEN, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| EP-0602851-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1994-06-22 | — | — | EP | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
| US-4134980-A | Phenylalkylamino-alkyl derivatives of quinazolinone and phthalazinone | BOEHRINGER INGELHEIM GMBH (DE) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | ERBB4, ABL1, KRAS | SRC 308/4885PARP1 1318/4885CHEK1 323/4885 |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | SRC 3638/4885PARP1 1913/4885CHEK1 4564/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | SRC 474/4885PARP1 2948/4885CHEK1 274/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | SRC 4226/4885PARP1 982/4885CHEK1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.